FDA WARNING_LETTER - NuScience Peptides LLC - August 03, 2026

On August 24, 2026, the FDA issued a warning letter to NuScience Peptides LLC following a July 2026 review of the company’s website. The agency identified several products—including various GLP-1 and GLP-2 research peptides, Retatrutide, Survodutide, and PT-141—as unapproved new drugs. Despite the company labeling these items for "research use only," the FDA determined they are intended for human use based on website claims regarding their ability to treat conditions such as obesity, type 2 diabetes, and sexual dysfunction. The FDA expressed specific concern regarding the injectable nature of these products, which can pose significant health risks by bypassing the body"s natural defenses. Under the Federal Food, Drug, and Cosmetic Act, distributing these substances in interstate commerce without official FDA approval is a violation of federal law. To address these findings, NuScience Peptides LLC must submit a written response within 15 business days detailing the corrective actions taken to resolve the violations and the steps implemented to prevent their recurrence. Failure to comply may result in legal action, including product seizure or injunctions.